[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cvd-risk\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cvd-risk":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100637749","an-observational-study-to-evaluate-treatment-patterns-in-high-very-high-and-extreme-cardiovascular-risk-patients-with-hypercholesterolemia-including-familial-hypercholesterolemia-100637749",false,"NCT07606118","An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia","An Observational Longitudinal Multicenter Prospective Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia, Over a 1-Year Follow- Up","TRAP-HC","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of hypercholesterolemia (including clinical or genetic FH) OR high\u002Fvery high\u002Fextreme CV risk\n* Baseline visit within enrollment window (six months)\n\nExclusion Criteria:\n\n* Significant secondary dyslipidemia (e.g. hypertriglyceridemia)\n* Treatment changes due to non-hypercholesterolemia conditions","ALL","18 Years",{"count":20,"type":21},2500,"ESTIMATED","OBSERVATIONAL","TRAP-HC is a multicenter, observational, longitudinal, prospective study designed to evaluate real-world treatment patterns and lipid-lowering therapy (LLT) management in patients with hypercholesterolemia, including familial hypercholesterolemia (FH), who are at high, very high, or extreme cardiovascular risk. Approximately 2,500 adult patients will be enrolled across up to 15 Italian LIPIGEN network centers and followed for 12 months as part of routine clinical practice.\n\nThe study aims to assess LDL-C goal attainment according to current European guidelines, evaluate changes in lipid profiles over time, and investigate treatment adherence, persistence, and therapeutic modifications in response to clinical needs. Data collected during routine visits will include lipid parameters, cardiovascular history, concomitant therapies, safety outcomes, and patient-reported adherence measures.\n\nBy providing real-world evidence on the management of hypercholesterolemia in high-risk populations, the study seeks to identify current gaps between guideline recommendations and clinical practice and to support optimization of cardiovascular risk reduction strategies.",[25,26,27],"Hypercholesterolaemia","Familial Hypercholesterolaemia","CVD Risk",[29,30,31,32,33,34,35,36,37],"LDL Cholesterol","Lipid-Lowering Therapy","Cardiovascular risk","LDL-C goal attainment","Real-world evidence","Lipid Profil","Adherence to Lipid-Lowering Therapies","Changes in Treatment Regimens","Patient Attitudes and Clinical Practices","NOT_YET_RECRUITING","2026-08-20",{"date":41,"type":42},"2026-08-21","ACTUAL",{"date":44,"type":21},"2026-10-01",{"date":46,"type":21},"2028-04-01",{"name":48,"class":49},"Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100652074","elucidating-the-effect-of-dietary-stearic-acid-on-the-regional-heterogeneity-of-the-gut-microbiome-and-metabolome-focus-on-bile-acid-metabolism-sampill-study-100652074","NCT07766915","Elucidating the Effect of Dietary Stearic Acid on the Regional Heterogeneity of the Gut Microbiome and Metabolome: Focus on Bile Acid Metabolism (SAMPill Study)","Elucidating the Effect of Dietary Stearic Acid on the Regional Heterogeneity of the Gut Microbiome and Metabolome: Focus on Bile Acid Metabolism","SAMPill","Inclusion Criteria:\n\n1. Postmenopausal women (defined as complete natural cessation of menses for \\>12 months or a bilateral oophorectomy), who are not currently using hormone replacement therapy (HRT) or gender-affirming hormone treatments\n2. Age \\>50 years\n3. BMI \\>20 to \\\u003C35 kg\u002Fm2, inclusive\n4. Non-smoker or former smoker who quit \\> 6 months\n5. Normotensive with or without medication\n6. Normal gastrointestinal function with regular bowel movements at least once every other day\n7. Willingness to swallow the mini-pills\n8. Willingness to collect and return multiple stool samples\n9. Adequate refrigerator and freezer space to store study meals\n10. Intent to remain in the greater Boston area during the intervention periods\n\nExclusion Criteria:\n\n1. Allergy\u002Fintolerance\u002Freligious reasons to avoid study meals or food ingredients\n2. Regular use of dietary supplements, pre\u002Fprobiotics, laxatives or fiber supplements (except multivitamins) within the past 3 months\n3. Use of steroids (excluding topical) within the past 3 months\n4. Regular use of aspirin (except baby aspirin), NSAIDS, or anti diarrheal medication\n5. Current smokers or former smokers who quit \\\u003C 6 months ago, and use of nicotine replacement products within the last 6 months\n6. Chronic constipation\n7. Use of oral antibiotics within the past 3 months.\n8. Use of dental prophylaxis within the past 3 months\n9. Regular use of stomach acid lowering and weight loss medications such as GLP-1 agonists\n10. Planned colonoscopy 3 months prior to or during the study period\n11. Swallowing disorder or inability or difficulty taking pills\n12. Malabsorptive and inflammatory bowel disease, diverticulosis, and history of diverticulitis, gastric esophageal\u002Fintestinal surgery, including lap banding or bariatric surgery.\n13. History of bowel obstruction, gallstones, gastroparesis, pancreas and liver\u002Fgallbaldder disorders.\n14. Any form of active substance abuse or dependence (including drug or alcohol abuse).\n15. Established major chronic diseases such as CVD, diabetes, active cancer within the last 5 years, or any significant medical condition at the study MD's discretion\n16. A clinical condition that, in the judgment of the study MD or PI, could potentially pose a health risk to the subject while involved in the study.\n17. Unwillingness to adhere to study protocol\n18. Intent to increase or decrease body weight during the study period\n19. No Social Security number (for payment and IRS forms).\n20. Individuals who directly report to any member of the research team.","FEMALE","50 Years",{"count":61,"type":21},20,"INTERVENTIONAL",[64],"NA","Stearic acid and palmitic acid are two common consumed saturated fatty acids found in foods. Palmitic acid is associated with increases in blood cholesterol, whereas stearic acid is generally considered neutral with respect to blood cholesterol. However, the mechanisms underlying these different effects are not fully understood. The goal of this clinical trial is to determine how replacing dietary palmitic acid with stearic acid affects microorganisms living in the gastrointestinal tract (gut microbiome) and the metabolites they produce, including secondary bile acids, and whether these changes influence heart and metabolic health in postmenopausal women. The main question it aims to answer is whether the cholesterol lowering effect of dietary stearic acid, compared to dietary palmitic acid is due to changes in the composition and function of the gut microbiome and bile acid metabolism. Participants will consume a controlled diet high in palmitic acid for a 10-day run-in period, followed by a controlled diet high in stearic acid for 28 days. During the study, participants will provide biological samples, including blood samples collected in both fasting and non-fasting states, for assessment of cardiometabolic outcomes. Participants will also swallow mini-pills designed to collect samples from different regions of the gastrointestinal tract to assess the gut microbiome and related metabolites. Results will contribute to understanding the relationship between stearic acid mediated microbiota effects on cardiometabolic heath.",[27],[68,69,70,71,72,73],"stearic acid","bile acid metabolism","post-menopausal women","dietary intervention","saturated fatty acids","gut microbiome","2026-08-11",{"date":76,"type":42},"2026-08-17",{"date":78,"type":21},"2026-09",{"date":80,"type":21},"2029-08",{"name":82,"class":49},"Tufts University",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":17,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":62,"phases":96,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":83},"100648213","effectiveness-of-a-self-health-assessment-mobile-application-in-young-to-midlife-adults-in-hong-kong-100648213","NCT07720245","Effectiveness of a Self-health Assessment Mobile Application in Young-to-midlife Adults in Hong Kong","Effectiveness of Self-health Assessment Mobile Application to Promote Health Awareness, Empower Patients and Improve Linkage-to-care Amongst Young-to-midlife Adults in Hong Kong: a Randomised Controlled Trial","Inclusion Criteria:\n\n* Hong Kong residents self-reported age of 25-65 years;\n* Possesses a smartphone capable of running mobile apps (e.g. Android or iPhone) and;\n* Able to read either English or Chinese.\n\nExclusion Criteria:\n\n* Individuals having any symptoms or feeling unwell in anyways as detailed in the Disclaimer at the launch of the app; or\n* Individuals reporting a current diagnosis of cardiovascular disease, lung cancer, hepatitis B, colorectal cancer, diabetes, sexually transmitted diseases, depression, anxiety and mild cognitive impairment and memory loss.",true,"25 Years","65 Years",{"count":95,"type":21},574,[64],"This project aims to compare the effectiveness of Wellnuts, an evidence-based, algorithm-driven self-health assessment mobile application, in empowering asymptomatic young-to-midlife adults in Hong Kong, promoting health awareness, and improving health-seeking behaviour and linkage-to-care, compared with conventional web-based health resources. Participants will be randomly allocated to the mobile health intervention group (Wellnuts app with self-health assessment and health information) and the conventional web-based resources control group (health information from Centre for Health Protection website). Hopefully, population health will be improved with the general health promotion impact from the app.",[99,27,100,101,102],"Diabetes Risk","Colorectal Cancer","Lung Cancer","HBV",[104,105,106,107,108,109,110,111],"Self-health assessment","Mobile application","Health awareness","Health empowerment","Linkage-to-care","Chronic disease","Randomised control trial","Hong Kong","RECRUITING","2026-07-17",{"date":115,"type":42},"2026-07-22",{"date":117,"type":42},"2024-06-01",{"date":119,"type":21},"2027-03-31",{"name":121,"class":49},"The University of Hong Kong"]